Please assess the completion status of the following clinical trial:

Trial Title: AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ITP according to American Society of Hematology (ASH) guidelines (Appendix F)~* Have had a splenectomy for the treatment of ITP greater than or equal to 24 weeks prior to study entry~* Subjects greater than 60 years of age must have a documented history of chronic ITP with a bone marrow report to confirm the diagnosis~* The platelet count (calculated from the mean of the 2 counts taken during the screening and pre-treatment periods) must be:~* \* less than 30 x 10\^9/L for those subjects not receiving any ITP therapy, with no count greater than 35 x 10\^9/L,~* \* less than 50 x 10\^9/L for those subjects receiving a constant dose schedule of corticosteroids, azathioprine or danazol with no count greater than 55 x 10\^9/L~* A serum creatinine concentration less than or equal to 2 mg/dl(less than or equal to 176.8 µmol/L)~* Adequate liver function, as evidenced by a serum bilirubin less than or equal to 1.5 times the laboratory normal range~* Hemoglobin greater than 11.0 g/dL~* Written informed consent (see Section 12.1)~Exclusion Criteria:~* Any known history of bone marrow stem cell disorder (Any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled in the study)~* Any active malignancy. If prior history of cancer other than basal cell carcinoma or cervical carcinoma in situ, no treatment or active disease within 5 years before randomization~* Documented diagnosis of arterial thrombosis (i.e., stroke, transient ischemic attack or myocardial infarction) in the past year~* History of venous thrombosis (i.e., deep vein thrombosis, pulmonary embolism) including those subjects who are on ant-coagulation therapy~* Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure \[NYHA greater than class II\], uncontrolled hypertension \[diastolic greater than 100 mmHg\] or cardiac arrhythmia)~* Have 3 or more of the following predisposing factors for thromboembolic events: diabetes; smoker; using oral contraceptives; on estrogen therapy; known positive for anti-phospholipid antibodies; hypertriglyceridemia; hypercholesteremia (greater than 240 mg/dL); treatment for hypertension~* Known positive test for human immunodeficiency virus (HIV) infection or hepatitis C virus~* Currently receiving any treatment for ITP except corticosteroids, azathioprine or danazol administered at a constant dose and schedule~* IV Ig or anti-D Ig within 2 weeks before the screening visit~* Rituximab (for any indication) within 14 weeks before the screening visit or anticipated use during the time of the proposed study~* Received hematopoietic growth factors, including IL-11 (oprelvekin) within 4 weeks before the screening visit~* Past or present participation in any study evaluating PEG-rHuMGDF, recombinant human thrombopoietin (rHuTPO), AMG 531 or related platelet product~* Received any aklylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study~* Less than 4 weeks since receipt of any therapeutic drug or device that is not FDA approved for any indication before the screening period~* Less than 8 weeks since major surgery~* Pregnant or breast feeding~* Subjects of reproductive potential who are not using adequate contraceptive precautions, in the judgment of the investigator~* Known hypersensitivity to any recombinant E coli-derived product~* Concerns for subject's compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- AMG 531 (Type: EXPERIMENTAL): Active Investigational Product

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete